Venus Concept Inc announces it has received 510(k) clearance from the US Food and Drug Administration to market the Venus BlissMAX device in the United States.
BlissMAX is a medical aesthetic platform that offers a comprehensive solution for fat reduction, cellulite reduction, and muscle conditioning with three technologies in one platform. Like the Company’s Venus Bliss system, BlissMAX employs advanced diode laser applicators for non-invasive lipolysis of the abdomen and flanks in individuals with a BMI of 30 or less, resulting in reduction of unwanted focal fat, as well as an (MP) applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse technology to reduce the appearance of cellulite.
In addition to these technologies, BlissMAX also features the Company’s FlexMAX EMS applicators, designed for muscle conditioning to stimulate healthy muscles.
“We are very pleased to receive FDA 510(k) clearance for BlissMAX, the next generation of our Venus Bliss system, earlier than anticipated. BlissMAX is an important addition to our body treatment franchise, as we believe the integration of three body treatment technologies in a single, cost-effective platform will resonate with physician customers.
“The BlissMAX provides excellent results, has little-to-no downtime and offers compelling profitability per procedure for our customers. We look forward to initiating a limited commercial launch in the US by the end of the first quarter of 2022 and believe BlissMAX will be the only device on the market to offer laser fat reduction, cellulite reduction and muscle conditioning in a single body contouring workstation.”
— Domenic Serafino, Chief Executive Officer of Venus Concept
[Source(s): Venus Concept Inc, Globe Newswire]
